Associated Banc-Corp stock rises after dividend declaration and share buyback

Investing.com -- Venu Holding Corporation (NYSE:VENU) stock plunged 16.9% in after-hours trading Tuesday after the live music venue developer announced plans for a registered underwritten public offering of its common stock.

The company intends to offer approximately $75 million of shares, subject to market conditions, with an additional option for underwriters to purchase up to $11.25 million in shares to cover potential over-allotments. Deutsche Bank Securities and ThinkEquity are serving as joint book-running managers for the proposed offering.

Venu plans to use the proceeds to fund development costs for several projects including The Sunset McKinney, The Sunset Broken Arrow, and The Sunset El Paso. Funds will also go toward completing the purchase of real property in Centennial, Colorado, where the company plans to develop an indoor music hall and restaurant.

The announcement comes as Venu released preliminary fourth quarter and full-year 2025 results. The company estimates Q4 revenue between $4.4 million and $4.8 million, compared to $4.3 million in the same period of 2024. Total assets are projected to reach between $352.8 million and $355.4 million, nearly doubling from $178.4 million at the end of 2024.

Luxe FireSuite and Aikman Club sales for the full year 2025 are estimated between $125.3 million and $126.8 million, up from $77.7 million in 2024, representing a 62% increase. The company also recognized its first development profit of $6.2 million in the fourth quarter from a sale-leaseback of parking property at its Colorado Springs campus.

JW Roth, Chairman & CEO of VENU, stated that the company expects to become operationally profitable by the end of 2026 as several entertainment complexes near completion.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Investing.com -- Bank of Montreal’s capital markets division has appointed Aman Malik as its new chief operating officer, replacing Nina Knezevic as part of a leadership reorganization.

Malik, who previously served as head of strategy and chief administration officer for banking at Wells Fargo & Co., will report directly to Alan Tannenbaum, the chief executive of BMO Capital Markets, according to reporting from Bloomberg, citing a person familiar with the matter who requested anonymity.

Knezevic, who currently holds the COO position at the unit, will transition to a new role as head of strategic workforce planning and initiatives for Bank of Montreal, the source said.

This executive change represents the latest leadership adjustment at the firm’s capital markets division.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Investing.com -- StandardAero, Inc. (NYSE:SARO) stock dropped 4.1% in after-hours trading Tuesday following an announcement that two of its major stockholders plan to sell 50 million shares in a public offering.

The selling stockholders, affiliates of The Carlyle Group Inc. and GIC, will receive all proceeds from the proposed offering, with StandardAero not receiving any funds from the transaction. The stockholders also expect to grant underwriters a 30-day option to purchase up to an additional 7.5 million shares.

Morgan Stanley & Co. LLC, J.P. Morgan, and RBC Capital Markets are acting as joint lead book-running managers for the offering, while Carlyle is serving as co-manager.

Concurrent with the public offering, StandardAero has agreed to repurchase $50 million of its common stock from one of the selling stockholders in a private transaction. The repurchase price will equal the price paid by underwriters in the offering. This share repurchase will be executed under StandardAero’s existing stock repurchase program approved by its board in December 2025.

The offering remains subject to market conditions, with no guarantee regarding its completion or final terms. The share repurchase is contingent upon the completion of the public offering, though the offering itself is not dependent on the repurchase transaction.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Investing.com -- The U.S. Centers for Medicare & Medicaid Services (CMS) on Tuesday announced a new list of branded medications for the third round of the Medicare Drug Price Negotiation Program.

The latest selection includes drugs from major pharmaceutical companies such as Eli Lilly, Pfizer, and AbbVie.

This third cycle marks the first time that products covered under Medicare Part B have been included in the negotiation program. Medicare Part B typically covers medications administered in outpatient settings or doctor’s offices.

The Medicare Drug Price Negotiation Program was established to help reduce prescription drug costs for Medicare beneficiaries through direct price negotiations between the federal government and pharmaceutical manufacturers.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.